Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for more analysis.
Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback